Radioactive therapy takes aim at Hard-to-Treat kidney cancer
NCT ID NCT06964958
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a radioactive drug called 177Lu-PSMA-617 (Pluvicto) in 24 people with advanced clear cell kidney cancer that shows a specific marker (PSMA). The drug is given by IV and aims to shrink tumors. Researchers are measuring how many patients respond and tracking side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (Pluvicto), a radioactive drug given by IV
What this could lead to
If successful, this could offer a new treatment option for advanced kidney cancer that has not responded to other therapies.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Radioactive drugs can cause side effects like fatigue, low blood counts, or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States